Eli Lilly (NYSE:LLY) Stock Upgrade
Barclays has increased shares of Eli Lilly (NYSE:LLY) to a “Overweight” in a very recent research note distributed on moments ago, and has published a one year target PPS equal to $95.0. LLY’s previous stock rating was a “Equal Weight”.
From a total of 19 analysts covering Eli Lilly and Company (NYSE:LLY) stock, 14 rate it a ”Buy”, 0 a “Sell”, and 7 a ”Hold”. This means that 67% of the ratings are positive. The highest target price is $121 while the lowest target price is $82. The mean of all analyst targets is $97.53 with a 17.57% above today’s ($85.76) stock price. Eli Lilly and Company was the topic of 21 analyst reports since July 23, 2015 according to the firm StockzIntelligence Inc. Barclays Capital upgraded shares on December 1 to “Overweight” rating. Leerink Swann maintained LLY stock in a recent report from November 12 with “Outperform” rating. Finally, Cowen & Co maintained the stock with “Outperform” rating in a report issued on an August 24.
Approximately 3.84M shares of stock traded hands. Eli Lilly and Co (NYSE:LLY) has risen 15.26% since April 28, 2015 and is uptrending. It has outperformed by 16.88% the S&P500.
Eli Lilly and Company is engaged in drug manufacturing business. The company has a market cap of $96.68 billion. The Firm discovers, develops, makes and market products in two divisions: human pharmaceutical products and animal health products. It has 38.72 P/E ratio. The Company’s products are sold in approximately 120 countries.
According to Zacks Investment Research, “Eli Lilly and Company discovers, develops, manufactures, and sells products in one significant business segment -pharmaceutical products. The company directs its research efforts primarily toward the search for products to diagnose, prevent and treat human diseases. The company also conducts research to find products to treat diseases in animals and to increase the efficiency of animal food production.” Get a free copy of the Zacks research report on Eli Lilly and Co (LLY)